Eustachio Nettis,1 Maddalena D’Erasmo,1 Elisabetta Di Leo,1 Gianfranco Calogiuri,2
Vincenzo Montinaro,3 Antonio Ferrannini,1 and Angelo Vacca1, 4
1 Section of Allergology and Clinical Immunology, Department of Internal Medicine and Infectious Diseases,
University of Bari Medical School, Piazza Giulio Cesare, 70124 Bari, Italy
2 Fourth Pneumology Department, Pneumologic Hospital A. Galateo, San Cesario di Lecce, Italy
3 Division of Nephrology, Department of Emergency and Organ Transplantation, University of Bari,
Azienda Ospedaliera “Policlinico”, 70124 Bari, Italy
4 Department of Internal Medicine and Clinical Oncology, University of Bari Medical School, 70124 Bari, Italy
Correspondence should be addressed to Eustachio Nettis, e.nettis@allergy.uniba.it
Received 14 December 2009; Revised 12 May 2010; Accepted 2 September 2010
Academic Editor: Muzamil Ahmad
Copyright © 2010 Eustachio Nettis et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Leukotrienes (LTs) are potent biological proinflammatory mediators. LTC4, LTD4, and LTE4 are more frequently involved in
chronic inflammatory responses and exert their actions binding to a cysteinyl-LT 1 (CysLT1) receptor and a cysteinyl-LT 2 (CysLT2)
receptor. LTs receptor antagonists available for clinical use demonstrate high-affinity binding to the CysLT1 receptor. In this
paper the employment of anti-LTs in allergic cutaneous diseases is analyzed showing that several studies have recently reported
a beneficial effects of these agents (montelukast and zafirlukast as well as zileuton) for the treatment of some allergic cutaneous
related diseases-like chronic urticaria and atopic eczema although their proper application remains to be established.
Vincenzo Montinaro,3 Antonio Ferrannini,1 and Angelo Vacca1, 4
1 Section of Allergology and Clinical Immunology, Department of Internal Medicine and Infectious Diseases,
University of Bari Medical School, Piazza Giulio Cesare, 70124 Bari, Italy
2 Fourth Pneumology Department, Pneumologic Hospital A. Galateo, San Cesario di Lecce, Italy
3 Division of Nephrology, Department of Emergency and Organ Transplantation, University of Bari,
Azienda Ospedaliera “Policlinico”, 70124 Bari, Italy
4 Department of Internal Medicine and Clinical Oncology, University of Bari Medical School, 70124 Bari, Italy
Correspondence should be addressed to Eustachio Nettis, e.nettis@allergy.uniba.it
Received 14 December 2009; Revised 12 May 2010; Accepted 2 September 2010
Academic Editor: Muzamil Ahmad
Copyright © 2010 Eustachio Nettis et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Leukotrienes (LTs) are potent biological proinflammatory mediators. LTC4, LTD4, and LTE4 are more frequently involved in
chronic inflammatory responses and exert their actions binding to a cysteinyl-LT 1 (CysLT1) receptor and a cysteinyl-LT 2 (CysLT2)
receptor. LTs receptor antagonists available for clinical use demonstrate high-affinity binding to the CysLT1 receptor. In this
paper the employment of anti-LTs in allergic cutaneous diseases is analyzed showing that several studies have recently reported
a beneficial effects of these agents (montelukast and zafirlukast as well as zileuton) for the treatment of some allergic cutaneous
related diseases-like chronic urticaria and atopic eczema although their proper application remains to be established.
Hindawi Publishing Corporation
Mediators of Inflammation
Volume 2010, Article ID 628171, 6 pages
doi:10.1155/2010/628171
Mediators of Inflammation
Volume 2010, Article ID 628171, 6 pages
doi:10.1155/2010/628171
Tidak ada komentar:
Posting Komentar